Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol vs Aspirin in Cerebral Small Vessel Disease
NCT01932203Phase 4Unknown
- Sponsor
- Inha University Hospital
- Start
- Jul 2013
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cilostazol in Cerebral Small Vessel Disease (CSVD) (2 arms), sponsored by Inha University Hospital. Primary endpoint: Volume of white matter changes at 104 weeks. Status: unknown.
02
Drugs
cilostazol
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT01932203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01932203.